Search

The article discusses a study on peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients undergoing combined anti-CD73/anti-PD-L1 immunotherapy. The study aimed to identify blood-based immunophenotypic signatures to improve patient selection, response monitoring, and personalized targeting of immunosuppressive mechanisms. Results showed differences in leukocyte subsets between short-term and long-term survivors, with potential biomarkers identified for treatment personalization and response monitoring. However, further validation through larger-scale studies is necessary. [Extracted from the article]

A patent has been issued for personalized methods for detecting circulating tumor DNA by Myriad Women's Health Inc. The patent describes assays and methods for detecting disease-associated mutations, including tumor-specific somatic mutations, in a non-invasive manner. These methods aim to accurately determine tumor fraction in cancer patients and detect fetal disease-associated mutations in a non-invasive manner, addressing the need for early detection and preparation for genetic disorders in unborn fetuses. [Extracted from the article]

The patent application by inventors FOEGH, Marie and KNUDSEN, Steen focuses on methods for treating cancer using stenoparib and dovitinib. The dosing regimen involves administering specific doses of these compositions to cancer patients, particularly those with ovarian, breast, colon, pancreatic, or prostate cancer. The application emphasizes the need for improved cancer treatment methods and highlights the importance of personalized medicine based on biomarker analysis. [Extracted from the article]

A patent has been issued to Roche Diagnostics Operations Inc. for the use of ratios of sFlt-1 to PlGF or endoglin to PlGF as biomarkers for predicting preeclampsia-related adverse outcomes after childbirth. Preeclampsia is a serious condition that affects 2 to 8 percent of pregnancies and can lead to maternal and fetal mortality. The patent aims to provide a method for identifying women at risk of developing postpartum preeclampsia, eclampsia, or HELLP syndrome immediately after giving birth, allowing for timely intervention and management. [Extracted from the article]

The University of Chicago conducted a study on breast cancer, focusing on the use of quantitative biomarkers to determine the likelihood of achieving breast-conserving surgery after neoadjuvant systemic therapy for early-stage, hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. The research found that patients with high 21-gene recurrence scores, lower estrogen receptor/progesterone receptor expression, or higher Ki-67 expression were more likely to undergo breast-conserving surgery after neoadjuvant chemotherapy. However, disparities were observed, with Asian women and uninsured individuals being less likely to undergo breast-conserving surgery. The study highlights the need for ongoing research to select the most appropriate neoadjuvant systemic therapy based on quantitative biomarkers and genomic assay scores. [Extracted from the article]

A recent study conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, focused on the effectiveness of abemaciclib, trastuzumab, and fulvestrant in treating hormone receptor-positive, HER2-positive advanced breast cancer. The research found that this combination therapy improved progression-free survival compared to standard chemotherapy. The study also explored biomarkers and overall survival rates, with promising results for certain subtypes of breast cancer. Financial support for the study was provided by Eli Lilly. [Extracted from the article]

A recent study conducted at the University Medical Center Ljubljana in Slovenia focused on the potential of extracellular vesicle (EV) characteristics in local fluid and plasma as diagnostic biomarkers for high-grade serous carcinoma (HGSC). The researchers found significant differences in EV concentration and size distribution between HGSC patients and the control group, suggesting that EVs could serve as promising biomarkers for early detection of this aggressive disease. Further research on size-dependent molecular profiling of EVs may lead to the identification of novel diagnostic biomarkers for HGSC. [Extracted from the article]

A recent study conducted at Izmir Katip Celebi University Ataturk Training and Research Hospital in Turkey explored the prognostic role of survivin expression in breast cancer through a systematic review and meta-analysis. The researchers found that survivin expression was associated with poor prognosis in breast cancer patients, indicating its potential as a prognostic marker for guiding treatment decisions. The study analyzed 24 retrospective studies on overall survival and 15 studies on disease-free survival, concluding that survivin expression could serve as a valuable marker in breast cancer management. [Extracted from the article]

A study conducted by researchers at NITTE (Deemed to be University) in India focused on the impact of yoga intervention on inflammatory markers in newly diagnosed breast cancer patients undergoing conventional treatment. The study included 44 patients at various stages of breast cancer who were undergoing chemotherapy followed by surgery. While the study did not show statistically significant differences between the yoga intervention group and the control group, it did indicate a consistent downregulation of proinflammatory markers over time in the yoga group. The researchers concluded that incorporating yoga as a complementary therapy alongside conventional breast cancer treatment could improve health outcomes by modulating proinflammatory markers. [Extracted from the article]

Researchers at Henan University of Science and Technology conducted a study on breast cancer, focusing on the role of CD8 + T cells in identifying genetic markers that enhance prognosis and immunotherapy efficacy. The study developed a CD8 + T cell-related gene prognostic signature using machine learning algorithms and validated it across multiple datasets. The findings suggest that the developed signature improves early diagnosis and treatment precision in breast cancer, with potential therapeutic implications for key genes like TTK. The research was supported by various funding sources and published in BMC Cancer. [Extracted from the article]

Researchers from Tehran University of Medical Sciences conducted a study to predict immunohistochemical biomarkers in breast cancer using radiomic features from F-18-FDG PET/CT images. The study included 62 patients with locally advanced breast cancer, and machine learning classifiers based on PET, CT, and PET/CT radiomic features were found to correlate with the immunohistochemical biomarkers. The research was supported by various institutions and concluded that these predictive models could be valuable in diagnosing breast cancer. The study was published in the Journal of Medical and Biological Engineering and can be accessed online. [Extracted from the article]

A recent systematic review conducted at SRM Dental College in Tamil Nadu, India, focused on using saliva as a diagnostic biomarker in postmenopausal women. The study aimed to identify salivary markers for diagnosing diseases in this population, with a particular emphasis on osteoporosis. The research highlighted the need for larger studies to validate the efficacy of salivary biomarkers such as calcium levels in detecting early bone changes and diagnosing osteoporosis in postmenopausal women. For more information, the full article can be accessed through the Journal of Datta Meghe Institute of Medical Sciences University. [Extracted from the article]

Researchers at Anhui Medical University in China have utilized ultrasound genomics to develop a signature that can predict breast cancer prognosis and chemotherapy response. By analyzing ultrasound images and transcriptome data, they identified key ultrasound features and genes associated with long-term survival and chemotherapy response. This signature not only aids in patient stratification for personalized treatment pathways but also highlights VPS28 as a significant biomarker linked to poor prognosis and tumor invasiveness. The study underscores the potential of ultrasound genomics in enhancing prognostic assessment and treatment prediction for breast cancer patients. [Extracted from the article]

A recent study conducted by researchers at Brigham Young University focused on triple-negative breast cancer (TNBC), a subtype that lacks commonly targeted membrane markers and has lower survival rates. The study analyzed 196 samples from 10 RNA-sequencing studies to identify potential mechanistic markers for TNBC treatment. The findings, including differentially expressed genes and pathways, aim to improve diagnostics and treatment options for TNBC patients. The research provides valuable insights into the molecular mechanisms of TNBC, offering potential advancements in understanding and managing the disease. [Extracted from the article]

Researchers at Swansea University have developed new non-invasive biomarkers for pre-eclampsia using computational models to analyze cardiovascular signals in pregnant women. The study identified two novel biomarkers, PPI and RI, which can differentiate between pre-eclamptic and non-pre-eclamptic patients more effectively than traditional measures. This research offers promising advancements in the diagnosis and classification of pre-eclampsia, particularly in cases where non-invasive measurements are not feasible. For more information, the full article can be accessed in Scientific Reports. [Extracted from the article]

Researchers at Sun Yat-sen University Cancer Center in Guangzhou, China, have conducted a study on biomarkers to improve the efficacy of immunotherapy for triple-negative breast cancer (TNBC). TNBC is a highly aggressive subtype with limited treatment options, and immunotherapy has shown promise but faces challenges due to tumor heterogeneity and therapy resistance. The study emphasizes the need for further research to identify additional biomarkers and refine tailored therapies for specific TNBC subtypes to enhance survival outcomes for patients. The research was published in Frontiers in Immunology and can be accessed for free online. [Extracted from the article]

A recent study conducted by researchers at the University of California focused on the impact of breast cancer therapy on biological aging in survivors. The study analyzed gene expression related to cellular senescence, DNA damage response, and inflammatory processes in women diagnosed with breast cancer. The findings suggest that women treated for breast cancer show signs of aging within their immune cells, with differences observed in gene activation patterns based on the type of treatment received. This research sheds light on the biological effects of breast cancer treatment on survivors' health and aging processes. [Extracted from the article]

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center found that common breast cancer treatments, such as chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors. The research, published in the Journal of the National Cancer Institute, revealed that markers of cellular aging increased significantly in all breast cancer survivors, regardless of the treatment received. This study highlights the importance of understanding the impact of breast cancer treatments on the body to better target and manage aging-related conditions in survivors. The team is now exploring new biomarkers to measure biological age and investigate factors that may influence the aging process in breast cancer survivors. [Extracted from the article]

SPA Farma and Inbiomotion have signed an exclusive agreement to offer the MAF Test(R) in Italy, a diagnostic tool for identifying high-risk early-stage breast cancer patients. The test helps oncologists predict patient prognosis, personalize treatment, and determine who may benefit from bisphosphonate therapy. This collaboration aims to improve patient outcomes, reduce unnecessary treatments, and enhance the quality of life for those battling breast cancer in Italy. The MAF Test(R) has shown promising results in clinical trials, with 80% of patients benefiting from bisphosphonate treatment, while those with MAF-positive tumors did not see the same benefits. [Extracted from the article]

A clinical trial, NCT06618872, is being conducted in Switzerland to investigate the clinical validity of tau-PET with [18F]RO948 compared to amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia. The trial aims to assess the diagnostic confidence and changes in diagnoses between the two imaging techniques, as well as evaluate the accuracy of clinical and biomarker-based diagnoses and predict cognitive decline and dementia onset. The trial is not yet recruiting and aims to enroll 120 participants between the ages of 50 and 85. Valuable information from this study will help establish appropriate diagnostic algorithms for these conditions. [Extracted from the article]

A recent study conducted by researchers at the University of Hong Kong aimed to examine the relationship between adipogenesis (the process of fat cell development) and breast cancer outcomes. The study conducted a systematic review and meta-analysis of 11 studies and identified several potential biomarkers for predicting breast cancer recurrence, including FASN, Spot 14, pS6K1, lipin-1, PLIN2, Elovl6, and PPARg. The study found that adipogenesis biomarkers were a significant predictor of long-term recurrence, independent of hormone receptor status, HER2 status, and ki-67. Further research is needed to uncover specific biomarkers for diagnosis and prediction. [Extracted from the article]

A recent report from the University of Maryland discusses the use of thermography as a supplementary diagnostic tool for breast cancer. The study focuses on the application of matrix factorization methods and Rayleigh embedding to enhance the reliability of thermal patterns in breast abnormalities. The research shows promising preliminary outcomes and suggests that this non-invasive tool can aid in the early detection of breast cancer. For more information, readers can refer to the article "Diagnostic Biomarker for Breast Cancer Applying Rayleigh Low-Rank Embedding Thermography" published in Engineering Proceedings. [Extracted from the article]

A recent study conducted at University Hospital Sant Joan de Reus in Spain explored the metabolic changes in breast cancer patients following different treatments. The study included 52 women diagnosed with breast cancer who underwent surgery, radiotherapy, and other treatments. The researchers found that the treatments led to favorable metabolic changes, including a decrease in pathways that promote cell proliferation and an increase in levels of anticancer molecules. These findings highlight the importance of metabolomics in understanding the effects of cancer treatments and identifying potential biomarkers for disease progression. [Extracted from the article]

A recent study conducted by researchers from the National Cancer Institute in Aviano, Italy, explores the potential of liquid biopsies in the management of triple-negative breast cancer (TNBC). The study highlights the limitations of current biomarkers and suggests that liquid biopsies, such as circulating tumor cell characterization and circulating tumor DNA, could be valuable tools for determining treatment efficacy, detecting early relapse, and monitoring clonal evolution during treatment. The researchers believe that these biomarkers may play a crucial role in identifying early disease relapse, therapeutic targets, and disease clonality in TNBC patients. The study was supported by the Ministry of Health in Italy. [Extracted from the article]

A study conducted by researchers at Charles University in Prague aimed to develop predictive models for adverse pregnancy outcomes based on miRNA biomarkers and maternal clinical characteristics. The study included pregnancies with various complications such as gestational hypertension, preeclampsia, fetal growth restriction, and gestational diabetes mellitus. The results showed that the proposed models had a high predictive potential for identifying women at increased risk of adverse pregnancy outcomes. The researchers suggest that implementing preventive programs based on these models could lower cardiovascular risk and prevent the development of metabolic/cardiovascular/cerebrovascular diseases. [Extracted from the article]

A recent study conducted at Baylor College of Medicine in Houston, Texas, has identified potential biomarkers for the detection of ectopic pregnancy (EP), which is a leading cause of maternal morbidity and mortality in the first trimester. The researchers used an untargeted metabolomic approach and identified several altered molecular features in the plasma of EP cases compared to controls. The top regression model, consisting of D-erythro-sphingosine and oleoyl-carnitine, achieved high accuracy in detecting EP. These findings suggest that these metabolite biomarkers could potentially improve early diagnosis of EP in the future. [Extracted from the article]

A recent study conducted at the Hirszfeld Institute of Immunology and Experimental Therapy explored the effects of vitamin D3 on tumor-associated macrophages (TAMs) in breast cancer patients. The researchers found that vitamin D3 and its active metabolite, calcitriol, reduced the expression of M1 and M2 macrophage markers in breast cancer patients. This suggests that vitamin D3 has immunomodulatory and anticancer effects. The study also found that the effects of vitamin D3 were most pronounced in postmenopausal patients without metastases. Further research is needed to fully understand the potential of vitamin D3 in breast cancer treatment. [Extracted from the article]

A recent study conducted at Istanbul Training and Research Hospital in Turkey explored the relationship between fasting bile acid (FBA) levels and hyperemesis gravidarum (HG), a condition characterized by severe nausea and vomiting during pregnancy. The study found that FBA levels were significantly higher in pregnant women diagnosed with HG compared to healthy pregnant women. The researchers suggest that FBA levels could serve as a biomarker for diagnosing HG and indicating early-stage liver damage. However, further research with larger cohorts is needed to validate these findings. [Extracted from the article]

A recent report from the Second Hospital of Jilin University in Changchun, China explores the connection between the gut microbiota and female infertility. The researchers highlight that infertility is a growing global issue, with various factors contributing to the problem. They specifically focus on the role of the gut microbiota in conditions such as polycystic ovary syndrome (PCOS), endometriosis (EMs), and premature ovarian failure (POF). By studying the relationship between the gut microbiota and these infertility disorders, the researchers hope to provide new insights for diagnosing and treating female infertility. [Extracted from the article]

A recent study conducted at the University Medical Center Ljubljana in Slovenia explored the potential use of ATP7A expression and ceruloplasmin (CP) levels as biomarkers for predicting responses to platinum-based drugs (PtBMs) in ovarian cancer patients. The study included 28 patients with high-grade serous carcinoma (HGSC) who underwent neoadjuvant chemotherapy (NACT). The researchers found that higher ATP7A expression in the peritoneum before NACT was associated with an unfavorable CA-125 elimination rate constant k (KELIM) score, while omental ATP7A expression was linked to higher plasma CP levels before NACT. Plasma CP levels decreased significantly after NACT, and higher CP levels after NACT were associated with a shorter platinum-free interval (PFI). However, further research is needed to validate the clinical utility of ATP7A and CP as predictive markers of chemoresistance. [Extracted from the article]

A report from Rostov State Medical University discusses the research findings on endometriosis, a chronic hormone-dependent disease that affects up to 10% of women of reproductive age. The diagnosis of endometriosis is currently based on clinical presentation, ultrasound, and magnetic resonance imaging, but there is a lack of objective criteria. The article reviews the literature on molecular biological markers of endometriosis and their potential application in medical practice. The research excluded studies on invasive diagnostics, surgical treatment, and extragenital forms of endometriosis, resulting in the selection of 29 articles that reflect the current state of non-invasive and minimally invasive diagnosis of endometriosis. [Extracted from the article]

A recent report from Texas A&M University highlights the importance of early diagnosis for preeclampsia, a potentially life-threatening condition for pregnant women and their babies. The study focuses on the development and evaluation of aptamers, which are molecules that can bind to specific biomarkers associated with preeclampsia. The researchers found that these aptamers demonstrated strong binding affinities, comparable or superior to traditional antibodies. The findings suggest that these aptamers have the potential to be integrated into cost-effective, point-of-care diagnostic tools, improving early detection and intervention strategies for preeclampsia and ultimately leading to better maternal and fetal health outcomes. [Extracted from the article]

Researchers at the Department of Gynecology and Reproductive Medicine in Kashihara, Japan, have conducted a study on tissue factor pathway inhibitors (TFPI1 and TFPI2) and their role in ovarian cancer. TFPI2, which is known to be a tumor suppressor, has been found to be elevated in the blood of patients with gynecological cancers, including ovarian cancer. The study explores the mechanisms behind this elevation and discusses the contradictory functions of TFPI2 in human malignancies. This research provides valuable insights into the potential use of TFPI2 as a serodiagnostic marker for ovarian cancer. [Extracted from the article]

A new study conducted by researchers at the University Indonesia explores the use of microRNAs (miR-21 and miR-145) as prognostic biomarkers for radiotherapy responses in cervical cancer patients. The study found that elevated expression of miR-21 was significantly associated with radioresistance in cervical cancer patients, while miR-145 expression showed no significant correlation with treatment response. Combining miR-21 and miR-145 did not improve the predictive accuracy. These findings suggest that miR-21 may be a potential biomarker for predicting radiotherapy outcomes in cervical cancer patients. [Extracted from the article]

Mercy BioAnalytics, Inc. has published two companion papers in the Journal of Molecular Diagnostics, describing a novel technology platform and clinical verification of an ovarian cancer test. The technology platform, called the Mercy Halo, utilizes tumor-derived extracellular vesicles (EVs) as biomarkers for early-stage cancer detection. The test has shown high sensitivity and specificity in detecting high-grade serous carcinoma (HGSC), the most common and deadly subtype of ovarian cancer. These publications provide promising evidence of progress towards the development of a safe and effective ovarian cancer screening test for postmenopausal women. [Extracted from the article]

A recent report from investigators in Gujarat, India, discusses the use of Bodipys, a type of fluorescent marker, to monitor autophagic lysosomes and lipid droplets in triple negative breast cancer (TNBC) cells. The researchers synthesized and characterized two Bodipys, BD-1 and BD-2, which were found to preferentially colocalize in lysosomes and lipid droplets. The Bodipys were also shown to induce autophagy and release calcium ions in the cytoplasm. The study concludes that Bodipys have potential as theranostic agents for photodynamic therapy against TNBC. [Extracted from the article]

A new study published by researchers from the Paul Scherrer Institute in Switzerland explores the use of radioimmunotherapy to target cancer stem cells in ovarian cancer. Cancer stem cells are a population of tumor cells that have unique characteristics, such as self-renewal and resistance to conventional therapies. The study focuses on the L1 cell adhesion molecule (L1CAM) as a biomarker for ovarian cancer stem cells and discusses the potential of anti-L1CAM radioimmunotherapy as a novel treatment approach. The research highlights the need for a deeper understanding of cancer stem cell biology and the development of targeted therapies. [Extracted from the article]

A recent study conducted at Shin-Kong Wu Ho-Su Memorial Hospital in Taipei, Taiwan, has found that clustered circulating tumor cells (CTC) and microemboli (CTM) are promising biomarkers for monitoring breast cancer and predicting patient responses to treatment. The researchers examined 80 samples from 11 breast cancer patients during follow-up visits and used a microfluidic chip and imaging system to count the number of CTC and CTM. They found that CTM displayed a distinguishable distribution in stratified patients and had a better predictive value for disease progression compared to CTC. The study concludes that CTM and its subtypes are valuable tools for studying cancer metastasis and monitoring cancer patients during follow-up visits. [Extracted from the article]

A research paper published in Aging (Albany NY) and Aging-US explores the prevalence of frailty in breast cancer and hematopoietic cell transplant survivors and its impact on physical performance and quality of life. The study, conducted by researchers from the University of Minnesota, Amgen, and Columbia University Medical Center, found a high prevalence of frailty in these survivor groups, with detrimental effects on physical functioning and overall well-being. The study also identified an association between frailty and the senescence marker p16INK4a, suggesting the need for further research on senolytic trials in cancer survivors. [Extracted from the article]